New drug combo aims for deeper remission in tough blood cancers
NCT ID NCT07153497
First seen Nov 01, 2025 · Last updated Apr 10, 2026 · Updated 28 times
Summary
This study is testing if adding a new drug called olutasidenib to standard treatments helps patients with specific types of blood cancer. It is for adults newly diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that have a particular genetic change (IDH1 mutation). The main goal is to see if the new combination leads to a better and longer-lasting remission compared to standard care alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.